EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Treatment-Refractory Hypothyroidism due to Proteinuria During Combined Immune Checkpoint and Tyrosine Kinase Inhibitor Therapy – A Case Report

Jessica K Williams iD, Anne K Brinkman iD, Amori Y Salami-Henry, Nupur J Kikani, Steven P Weitzman iD

Clinical Medicine Insights: Endocrinology and Diabetes · 2026-07 · 19

DOI: 10.1177/11795514261471643 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Medicine Insights: Endocrinology and Diabetes, online erschienen am 18.07.2026. Verfasst von Jessica K Williams und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) are increasingly used in oncology and commonly cause thyroid dysfunction. Most patients who develop hypothyroidism after ICI-induced thyroiditis respond to standard weight-based levothyroxine replacement. However, causes of treatment-refractory hypothyroidism are less well recognized in this context. We describe an 81-year-old woman with uterine cancer treated with lenvatinib and pembrolizumab who developed ICI-related thyroiditis with subsequent hypothyroidism. Despite progressive levothyroxine dose escalation to nearly twice the expected weight-based dose, thyroid-stimulating hormone (TSH) remained elevated after normalization of free thyroxine (FT4) and triiodothyronine (T3). Evaluation for malabsorption and nonadherence was unrevealing. Further investigation identified significant proteinuria associated with lenvatinib therapy. Given that thyroid hormone circulates primarily bound to plasma proteins, urinary loss of protein-bound thyroid hormone was suspected to contribute to the increased levothyroxine requirement. Following temporary discontinuation and subsequent dose reduction of lenvatinib, proteinuria improved and thyroid function tests (TFTs) normalized, allowing for a reduction in levothyroxine dose. This case highlights that excessive proteinuria can lead to urinary loss of protein-bound thyroid hormone, resulting in apparent levothyroxine resistance. Clinicians should consider renal losses along with gastrointestinal and medication-related causes when thyroid hormone requirements exceed expected dosing. This is particularly relevant in patients receiving combination cancer therapies that increasingly include ICIs.

Schlagwörter

Stichwörter der Autor:innen

adverse eventcancerimmunotherapylenvatinibpembrolizumabproteinuriathyroidthyroxine treatment failure

Autor:innen und Institutionen

  • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

ORCID-Profile: Jessica K Williams, Anne K Brinkman, Steven P Weitzman

Zitieren

APA

Williams, J. K., Brinkman, A. K., Salami-Henry, A. Y., Kikani, N. J., & Weitzman, S. P. (2026). Treatment-Refractory Hypothyroidism due to Proteinuria During Combined Immune Checkpoint and Tyrosine Kinase Inhibitor Therapy – A Case Report. Clinical Medicine Insights: Endocrinology and Diabetes, 19. https://doi.org/10.1177/11795514261471643

Vancouver

Williams JK, Brinkman AK, Salami-Henry AY, Kikani NJ, Weitzman SP. Treatment-Refractory Hypothyroidism due to Proteinuria During Combined Immune Checkpoint and Tyrosine Kinase Inhibitor Therapy – A Case Report. Clinical Medicine Insights: Endocrinology and Diabetes. 2026;19. doi:10.1177/11795514261471643

BibTeX
@article{Williams2026,
  author = {Williams, Jessica K and Brinkman, Anne K and Salami-Henry, Amori Y and Kikani, Nupur J and Weitzman, Steven P},
  title = {Treatment-Refractory Hypothyroidism due to Proteinuria During Combined Immune Checkpoint and Tyrosine Kinase Inhibitor Therapy – A Case Report},
  journal = {Clinical Medicine Insights: Endocrinology and Diabetes},
  year = {2026},
  volume = {19},
  doi = {10.1177/11795514261471643}
}
Kostenlos starten →